Table 2. Clinicopathological and molecular characteristics of PD-L1+(I) versus PD-L1−(I) subgroups of MSI-H CRCs (n=208).
| Variables | No. of cases | PD-L1+(I) (n=62) | PD-L1−(I) (n=146) | P-value |
|---|---|---|---|---|
|
AJCC/UICC cancer stage | ||||
| Stage I/II | 136 (65%) | 50 (81%) | 86 (59%) | 0.003 |
| Stage III/IV | 72 (35%) | 12 (19%) | 60 (41%) | |
|
Peritumoural lymphoid reaction | ||||
| Absent/mild (grade 0/1) | 90 (45%) | 14 (23%) | 76 (54%) | <0.001 |
| Moderate/marked (grade 2/3) | 112 (55%) | 47 (77%) | 65 (46%) | |
|
Tumour-infiltrating T cell density | ||||
| Low (CD3+ cells/HPF <50) | 107 (52%) | 14 (23%) | 93 (64%) | <0.001 |
| High (CD3+ cells/HPF ⩾50) | 99 (48%) | 46 (77%) | 53 (36%) | |
|
Tumour-infiltrating macrophage density | ||||
| Low (CD68+ cells/HPF <45) | 102 (52%) | 18 (30%) | 84 (62%) | <0.001 |
| High (CD68+ cells/HPF ⩾45) | 95 (48%) | 43 (70%) | 52 (38%) | |
|
Mucinous component | ||||
| Absent | 89 (43%) | 34 (55%) | 55 (38%) | 0.022 |
| Present | 119 (57%) | 28 (45%) | 91 (62%) | |
Abbreviations: AJCC=American Joint Committee on Cancer; CRCs=colorectal cancers; HPF=high power field; MSI-H=microsatellite instability-high; PD-L1+(I)=PD-L1-positive in immune cells; PD-L1−(I)=PD-L1-negative in immune cells; UICC=International Union for Cancer Control.